Testing the safety of BNT351 in people with and without HIV
Part of Infections clinical trials.
This trial tests a new antibody called BNT351 to see if it is safe and how it affects the immune system. It is for adults who either do not have HIV, or have HIV and are not currently on HIV medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- If you do not have HIV, you must be HIV-negative and willing to avoid high-risk behaviors.
- If you have HIV, you must have a CD4 count of at least 500 and a viral load between 5,000 and 100,000 copies/mL.
- You cannot have received an HIV vaccine or a similar antibody in another study.
- You cannot have certain immune system problems or be on certain medications.
- If you have HIV, you cannot have certain infections or AIDS-defining illnesses.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new RNA-based vaccine called BNT168 to see if it is safe and how the body responds to it. It is for healthy adults with or without HIV, and those with HIV will pause their regular treatment for a while during the study.
This study tests a new combination of two drugs to see if they can reduce the 'hidden' HIV that stays in your body even when you're on regular HIV treatment. The goal is to work toward a cure, not just control.
This study tests whether giving two experimental drugs together can help your immune system find and destroy hidden HIV cells. It aims to see if this approach can reduce the amount of virus in your body even while you're on your regular HIV medications.
This trial tests a new combination of three medications, lenacapavir, teropavimab, and zinlirvimab, for people with HIV who currently have undetectable virus levels on a stable oral treatment. The goal is to see if these drugs can keep the virus suppressed, possibly allowing a simpler treatment plan.
This study tests a new drug, GS-0415, for people with HIV. The study will see if this drug can help control the virus. Participants will continue taking their regular HIV medication.
This study tests a new long-acting HIV medication taken by mouth that may allow you to switch from your current daily pill. It is for people who have had an undetectable HIV viral load for at least 6 months and are currently on a stable HIV treatment.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.